Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. A-002
2. Ly-333013
3. Ly333013
4. Methyl ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)acetate
5. S-3013
6. S3013
1. 172733-08-3
2. Ly333013
3. Ly-333013
4. A-002
5. Varespladib Methyl Ester
6. S-3013
7. Varespladib Methyl [usan]
8. 0nb98nbx3d
9. Ly 333013
10. S 3013
11. Methyl ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)acetate
12. Varespladib Methyl (usan)
13. Methyl ({3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1h-indol-4-yl}oxy)acetate
14. Methyl-varespladib
15. Acetic Acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)-, Methyl Ester
16. Methyl 2-((3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1h-indol-4-yl)oxy)acetate
17. Unii-0nb98nbx3d
18. Methyl Varespladib
19. Varespladib-methyl
20. Schembl25678
21. Chembl2105659
22. Dtxsid40938196
23. Chebi:192805
24. Xga73308
25. Zinc1550156
26. Varespladib Methyl Ester [mi]
27. Akos037643560
28. Cs-6574
29. Db05737
30. Sb16537
31. Ncgc00387871-03
32. As-16898
33. Hy-17448
34. D08221
35. Q7915615
36. Methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate
37. Methyl ((3-(aminooxoacetyl)-1-benzyl-2-ethyl-1h-indol-4-yl)oxy)acetate
| Molecular Weight | 394.4 g/mol |
|---|---|
| Molecular Formula | C22H22N2O5 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 9 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 101 |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 604 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in atherosclerosis and coronary artery disease.
Phospholipase A2 Inhibitors
Compounds that inhibit or block the activity of a PHOSPHOLIPASE A2 enzyme. (See all compounds classified as Phospholipase A2 Inhibitors.)
A002 is an orally administered potent inhibitor of secretory phospholipase spla2(spla2) including groups IIA V and X. Atherosclerosis is a disease of the arteries that results from inflammation and the build-up of plaque under the lining of the blood vessel. This build-up can cause vascular swelling and eventual rupture. spla2 levels have been shown to be elevated in patients with both stable and unstable coronary artery disease. Higher levels of the enzyme have been shown to predict an increased risk for future cardiovascular events such as heart attacks and stroke.
ABOUT THIS PAGE
82
PharmaCompass offers a list of Varespladib Methyl API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Varespladib Methyl manufacturer or Varespladib Methyl supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Varespladib Methyl manufacturer or Varespladib Methyl supplier.
PharmaCompass also assists you with knowing the Varespladib Methyl API Price utilized in the formulation of products. Varespladib Methyl API Price is not always fixed or binding as the Varespladib Methyl Price is obtained through a variety of data sources. The Varespladib Methyl Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Varespladib Methyl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Varespladib Methyl, including repackagers and relabelers. The FDA regulates Varespladib Methyl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Varespladib Methyl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Varespladib Methyl supplier is an individual or a company that provides Varespladib Methyl active pharmaceutical ingredient (API) or Varespladib Methyl finished formulations upon request. The Varespladib Methyl suppliers may include Varespladib Methyl API manufacturers, exporters, distributors and traders.
Varespladib Methyl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Varespladib Methyl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Varespladib Methyl GMP manufacturer or Varespladib Methyl GMP API supplier for your needs.
A Varespladib Methyl CoA (Certificate of Analysis) is a formal document that attests to Varespladib Methyl's compliance with Varespladib Methyl specifications and serves as a tool for batch-level quality control.
Varespladib Methyl CoA mostly includes findings from lab analyses of a specific batch. For each Varespladib Methyl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Varespladib Methyl may be tested according to a variety of international standards, such as European Pharmacopoeia (Varespladib Methyl EP), Varespladib Methyl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Varespladib Methyl USP).
